Hebei is a Major Pharmaceutical Province.

Hebei province is located in the neck of China, Beijing Tianjin Hebei region, and it is a major pharmaceutical province in Northern China. The pharma factories in Hebei are more than 330, exclude the private plants.

According to the data, in 2021, the added value of the pharmaceutical manufacturing industry above Designated Size in Hebei Province increased by 14.0%, 9.1% points higher than the provincial industrial average, and the added value of the pharmaceutical manufacturing industry accounted for 3.13% of the provincial industrial industry, an increase of 0.17% points over the previous year. In 2021, the pharmaceutical industry above designated size achieved an operating revenue of 106.879 billion RMB, an increase of 10.7% year-on-year; The total profit was 18.75 billion yuan, a year-on-year increase of 12.0%. Both scale and efficiency have been improved.


At the same time, the province’s innovation ability in the biomedical industry is also continuously enhanced. China Agricultural University model animal phenotype and genetic research national major scientific and technological infrastructure, chiral drug development national local joint engineering laboratory, North China Pharmaceutical microbial drug National Engineering Research Center and other innovation platforms have further enhanced their radiation driving effect, and the layout of major innovation platforms for life health and biotechnology in Xiong’An NEW area has been accelerated. Drug research and development has become increasingly active, with more than 300 clinical trials, ranking eighth in the country. Lianhua QingWen tablets, a class 1 Traditional Chinese medicine of Yiling pharmaceutical, was approved for listing, the innovative drug “Xuanning” of Shiyao group was certified to the highest international standards, and Huabei pharmaceutical anti rabies monoclonal antibody injection was approved for listing.

In addition to individual enterprises, characteristic industrial clusters have also accelerated their development. Shijiazhuang national biological industry base accelerates its development towards high-end aggregation, xiong’an new area accelerates the pace of undertaking Beijing’s non capital functions, Cangzhou Bohai New Area biomedical industrial park has become a centralized carrier for the transfer of Beijing Tianjin Pharmaceutical Enterprises and the transformation of scientific and technological achievements, the innovation and development pattern of Beidaihe life and health industry innovation demonstration zone has initially taken shape, and Anguo modern traditional Chinese medicine industrial park has accelerated the construction of a modern traditional Chinese medicine industry innovation agglomeration zone.

Post time: Jul-13-2022